Modafinil in Treating Fatigue in Patients Receiving Chemotherapy for Cancer

Last updated: October 13, 2015
Sponsor: Gary Morrow
Overall Status: Completed

Phase

3

Condition

Pain (Pediatric)

Treatment

N/A

Clinical Study ID

NCT00042848
CDR0000069477
URCC-U2901
U10CA037420
  • Ages 18-120
  • All Genders

Study Summary

RATIONALE: Modafinil may be effective in relieving fatigue in patients with cancer who are undergoing chemotherapy. The effectiveness of modafinil in relieving chemotherapy-related fatigue is not yet known.

PURPOSE: This randomized phase III trial is studying the effectiveness of modafinil in treating fatigue in patients who are receiving chemotherapy for cancer.

Eligibility Criteria

Inclusion

DISEASE CHARACTERISTICS:

  • Diagnosis of cancer

  • Concurrently receiving or has previously received chemotherapy and is scheduled for at least 3 additional courses of chemotherapy

  • Each course of chemotherapy must be at least 2 weeks in duration

  • No concurrent radiotherapy or interferon therapy

  • Brief Fatigue Inventory question #3 "fatigue worst" score of 2 or greater 1 week after first chemotherapy course

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • Not specified

Life expectancy

  • At least 6 months

Hematopoietic

  • Not specified

Hepatic

  • No uncontrolled anemia

Renal

  • Not specified

Cardiovascular

  • No history of clinically significant cardiac disease, including any of the following:

  • Unstable angina

  • Left ventricular hypertrophy

  • Ischemic echocardiogram changes

  • Chest pain

  • Arrhythmia

  • Other clinically significant manifestations of mitral valve prolapse in association with use of central nervous system stimulants (e.g., caffeine, amphetamines, or methylphenidate)

  • No uncontrolled hypertension

Gastrointestinal

  • Able to swallow medication

  • No narrowing (pathological or iatrogenic) or obstruction of the gastrointestinal tract

Other

  • No severe headaches

  • No glaucoma

  • No seizure disorder

  • No narcolepsy

  • No psychotic disorder

  • No Tourette's syndrome

  • No alcohol or drug abuse

  • Not pregnant or nursing

  • Fertile patients must use effective barrier contraception during and for at least 1 full menstrual cycle after study completion

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • See Disease Characteristics

Chemotherapy

  • See Disease Characteristics

Endocrine therapy

  • No concurrent chronic corticosteroids

Radiotherapy

  • See Disease Characteristics

Surgery

  • Not specified

Other

  • No prior modafinil

  • At least 30 days since prior regular use of psychostimulants (e.g., amphetamines, methylphenidate, or pemoline) or monoamine oxidase inhibitors (MAOIs)

  • No concurrent alcohol

  • Concurrent acetaminophen with codeine or hydrocodone bitartrate allowed

  • Concurrent phenytoin allowed

  • Concurrent warfarin for anticoagulation and low-dose warfarin (1 mg by mouth daily) for maintenance of venous access devices allowed

Study Design

Total Participants: 837
Study Start date:
August 01, 2002
Estimated Completion Date:
October 31, 2007

Study Description

OBJECTIVES:

  • Assess the degree to which modafinil can reduce fatigue in cancer patients receiving chemotherapy.

  • Assess the relationship between depression and fatigue in patients treated with this drug.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Beginning on day 5 of the second course of chemotherapy, patients receive oral modafinil once daily.

  • Arm II: Beginning on day 5 of the second course of chemotherapy, patients receive oral placebo once daily.

Treatment in both arms continues until day 7 of course 4 of chemotherapy in the absence of disease progression or unacceptable toxicity.

Fatigue and quality of life are assessed on day 7 of courses 2-4 of chemotherapy.

PROJECTED ACCRUAL: A total of 837 patients will be accrued for this study within approximately 2.5 years.

Connect with a study center

  • MBCCOP - Gulf Coast

    Mobile, Alabama 36606
    United States

    Site Not Available

  • CCOP - Western Regional, Arizona

    Phoenix, Arizona 85006-2726
    United States

    Site Not Available

  • CCOP - Santa Rosa Memorial Hospital

    Santa Rosa, California 95403
    United States

    Site Not Available

  • Medical Center of Aurora - South Campus

    Aurora, Colorado 80012-0000
    United States

    Site Not Available

  • Boulder Community Hospital

    Boulder, Colorado 80301-9019
    United States

    Site Not Available

  • Penrose Cancer Center at Penrose Hospital

    Colorado Springs, Colorado 80933
    United States

    Site Not Available

  • CCOP - Colorado Cancer Research Program

    Denver, Colorado 80224
    United States

    Site Not Available

  • Porter Adventist Hospital

    Denver, Colorado 80210
    United States

    Site Not Available

  • Presbyterian - St. Luke's Medical Center

    Denver, Colorado 80218
    United States

    Site Not Available

  • Rocky Mountain Cancer Centers - Denver Rose

    Denver, Colorado 80220
    United States

    Site Not Available

  • St. Joseph Hospital

    Denver, Colorado 80218-1191
    United States

    Site Not Available

  • Swedish Medical Center

    Englewood, Colorado 80112
    United States

    Site Not Available

  • Sky Ridge Medical Center

    Lone Tree, Colorado 80124
    United States

    Site Not Available

  • Rocky Mountain Cancer Centers - Longmont

    Longmont, Colorado 80501
    United States

    Site Not Available

  • St. Mary-Corwin Regional Medical Center

    Pueblo, Colorado 81004
    United States

    Site Not Available

  • Rocky Mountain Cancer Centers - Thornton

    Thornton, Colorado 80229
    United States

    Site Not Available

  • MBCCOP - Hawaii

    Honolulu, Hawaii 96813
    United States

    Site Not Available

  • MBCCOP - University of Illinois at Chicago

    Chicago, Illinois 60612-7323
    United States

    Site Not Available

  • CCOP - Central Illinois

    Decatur, Illinois 62526
    United States

    Site Not Available

  • CCOP - Evanston

    Evanston, Illinois 60201
    United States

    Site Not Available

  • CCOP - Wichita

    Wichita, Kansas 67214-3882
    United States

    Site Not Available

  • CCOP - Kalamazoo

    Kalamazoo, Michigan 49007-3731
    United States

    Site Not Available

  • CCOP - Metro-Minnesota

    St. Louis Park, Minnesota 55416
    United States

    Site Not Available

  • CCOP - Kansas City

    Kansas City, Missouri 64131
    United States

    Site Not Available

  • CCOP - Nevada Cancer Research Foundation

    Las Vegas, Nevada 89106
    United States

    Site Not Available

  • CCOP - Hematology-Oncology Associates of Central New York

    East Syracuse, New York 13057
    United States

    Site Not Available

  • CCOP - North Shore University Hospital

    Manhasset, New York 11030
    United States

    Site Not Available

  • CCOP - Southeast Cancer Control Consortium

    Goldsboro, North Carolina 27534-9479
    United States

    Site Not Available

  • CCOP - Columbus

    Columbus, Ohio 43215
    United States

    Site Not Available

  • CCOP - Dayton

    Dayton, Ohio 45429
    United States

    Site Not Available

  • CCOP - Columbia River Oncology Program

    Portland, Oregon 97225
    United States

    Site Not Available

  • CCOP - Greenville

    Greenville, South Carolina 29615
    United States

    Site Not Available

  • CCOP - Virginia Mason Research Center

    Seattle, Washington 98101
    United States

    Site Not Available

  • CCOP - Northwest

    Tacoma, Washington 98405-0986
    United States

    Site Not Available

  • CCOP - Marshfield Clinic Research Foundation

    Marshfield, Wisconsin 54449
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.